Stephen Hill - Lipocine Lead Independent Director

LPCN Stock  USD 5.44  0.12  2.26%   

Director

Dr. Stephen Anthony Hill, M.D., is Lead Independent Director of the Lipocine Inc. Dr. Hill has significant executive management experience in the therapeutics industry since 2014.
Age 58
Tenure 10 years
Professional MarksPh.D
Address 675 Arapeen Drive, Salt Lake City, UT, United States, 84108
Phone801 994 7383
Webhttps://www.lipocine.com
Hill currently serves as a director, President and Chief Executive Officer of Targacept Inc. . He has over 20 years of industry experience, having served previously as President and Chief Executive Officer of Solvay Pharmaceuticals, Inc., where he led an organization of over 1, 200 employees until its acquisition by Abbott Laboratories in 2010, and ArQule, Inc., where he led a successful transition for the company from a feeforservice discovery chemistry operation to a company with a proprietary clinicalstage pipeline. Prior to ArQule, Dr. Hill held several leadership positions with F. HoffmannLa Roche Ltd., including global head of clinical development. He is a Fellow of the Royal College of Surgeons of England and holds degrees in medicine and surgery from St. Catherine’s College at Oxford University.

Stephen Hill Latest Insider Activity

Tracking and analyzing the buying and selling activities of Stephen Hill against Lipocine stock is an integral part of due diligence when investing in Lipocine. Stephen Hill insider activity provides valuable insight into whether Lipocine is net buyers or sellers over its current business cycle. Note, Lipocine insiders must abide by specific rules, including filing SEC forms every time they buy or sell Lipocine'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.

Lipocine Management Efficiency

The company has return on total asset (ROA) of (0.3702) % which means that it has lost $0.3702 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.584) %, meaning that it created substantial loss on money invested by shareholders. Lipocine's management efficiency ratios could be used to measure how well Lipocine manages its routine affairs as well as how well it operates its assets and liabilities. As of the 19th of April 2024, Return On Tangible Assets is likely to drop to -0.75. In addition to that, Return On Capital Employed is likely to grow to -0.7. At this time, Lipocine's Total Assets are very stable compared to the past year. As of the 19th of April 2024, Other Assets is likely to grow to about 4 M, while Net Tangible Assets are likely to drop about 27 M.
The company currently holds 17.17 K in liabilities with Debt to Equity (D/E) ratio of 0.01, which may suggest the company is not taking enough advantage from borrowing. Lipocine has a current ratio of 21.79, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Lipocine until it has trouble settling it off, either with new capital or with free cash flow. So, Lipocine's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Lipocine sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Lipocine to invest in growth at high rates of return. When we think about Lipocine's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

DIRECTOR Age

Terrance McGuireIronwood Pharmaceuticals
61
Meredith KayaIronwood Pharmaceuticals
N/A
Howard LeeAmphastar P
55
John MartinDeciphera Pharmaceuticals LLC
57
Dan KisnerDynavax Technologies
67
Wendy DixonAlkermes Plc
62
Robert GlenningEagle Pharmaceuticals
57
Michael ZasloffAmphastar P
72
Andrew DreyfusIronwood Pharmaceuticals
59
Marsha FanucciIronwood Pharmaceuticals
64
Richard KooAmphastar P
77
Michael GravesEagle Pharmaceuticals
61
Jon DuaneIronwood Pharmaceuticals
59
Patricia AllenDeciphera Pharmaceuticals LLC
56
Laura BregeDynavax Technologies
60
Sander FlaumEagle Pharmaceuticals
81
James BristolDeciphera Pharmaceuticals LLC
71
Steven RatoffEagle Pharmaceuticals
81
Douglas BraunsteinEagle Pharmaceuticals
57
George ConradesIronwood Pharmaceuticals
76
Edward OwensIronwood Pharmaceuticals
71
Lipocine Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of neuroendocrine and metabolic disorders. The companys pipeline candidates also include LPCN 1144, an oral prodrug of bioidentical testosterone that has completed Phase II clinical trial for the treatment of non-cirrhotic non-alcoholic steatohepatitis LPCN 1111, an oral prodrug of testosterone tridecanoate for once daily dosing, which has completed Phase II clinical trial in hypogonadal men LPCN 1148, a novel prodrug of testosterone and testosterone laurate for the management of decompensated cirrhosis LPCN 1154, an investigational new drug application to conduct a Phase 2 study in Postpartum depression LPCN 2101 for women with epilepsy, which has completed pre-clinical study and LPCN 1107, an oral hydroxyprogesterone caproate product that has completed dose finding Phase II clinical trial for the prevention of recurrent preterm birth Lipocine (LPCN) is traded on NASDAQ Exchange in USA. It is located in 675 Arapeen Drive, Salt Lake City, UT, United States, 84108 and employs 17 people. Lipocine is listed under Pharmaceuticals category by Fama And French industry classification.

Management Performance

Lipocine Leadership Team

Elected by the shareholders, the Lipocine's board of directors comprises two types of representatives: Lipocine inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Lipocine. The board's role is to monitor Lipocine's management team and ensure that shareholders' interests are well served. Lipocine's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Lipocine's outside directors are responsible for providing unbiased perspectives on the board's policies.
Richard Ono, Director
Jeffrey Fink, Director
CPA CPA, Co Sec
Stephen Hill, Lead Independent Director
Gregory Bass, Executive Vice President Chief Commercial Officer
Logan Morse, Marketing Sales
John Higuchi, Non-Executive Director
Nachiappan Chidambaram, Senior Development
M MD, Chief Director
Mahesh Patel, Co-Founder, Chairman, CEO and Pres
Krista Fogarty, Principal Controller
Morgan Brown, CFO, Executive Vice President

Lipocine Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Lipocine a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Lipocine in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Lipocine's short interest history, or implied volatility extrapolated from Lipocine options trading.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Lipocine offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Lipocine's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Lipocine Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Lipocine Stock:
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lipocine. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators.
To learn how to invest in Lipocine Stock, please use our How to Invest in Lipocine guide.
Note that the Lipocine information on this page should be used as a complementary analysis to other Lipocine's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.

Complementary Tools for Lipocine Stock analysis

When running Lipocine's price analysis, check to measure Lipocine's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lipocine is operating at the current time. Most of Lipocine's value examination focuses on studying past and present price action to predict the probability of Lipocine's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lipocine's price. Additionally, you may evaluate how the addition of Lipocine to your portfolios can decrease your overall portfolio volatility.
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Money Managers
Screen money managers from public funds and ETFs managed around the world
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Is Lipocine's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lipocine. If investors know Lipocine will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lipocine listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(3.14)
Revenue Per Share
(0.54)
Quarterly Revenue Growth
(1.00)
Return On Assets
(0.37)
Return On Equity
(0.58)
The market value of Lipocine is measured differently than its book value, which is the value of Lipocine that is recorded on the company's balance sheet. Investors also form their own opinion of Lipocine's value that differs from its market value or its book value, called intrinsic value, which is Lipocine's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lipocine's market value can be influenced by many factors that don't directly affect Lipocine's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lipocine's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lipocine is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lipocine's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.